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Zurich, Basel, Bern, Switzerland; Heidelberg, Mannheim, Germany; Portland, Oregon, USA; Warsaw, PolandGRAPHICAL ABSTRACTBackground and Aims: Screening for colorectal cancer (CRC) can effectively reduce CRC incidence and mor-
tality. Besides colonoscopy, tests for the detection of biomarkers in stool, blood, or serum, including the fecal
immunochemical test (FIT), ColoGuard, Epi proColon, and PolypDx, have recently been advanced. We aimed
to identify the characteristics of theoretic, highly efficient screening tests and calculated the effectiveness and
cost effectiveness of available screening tests.
Methods: Using the microsimulation-based colon modeling open-source tool (CMOST), we simulated 142,501
theoretic screening tests with variable assumptions for adenoma and carcinoma sensitivity, specificity, test fre-
quency, and adherence, and we identified highly efficient tests outperforming colonoscopy. For available
screening tests, we simulated 10 replicates of a virtual population of 2 million individuals, using epidemiologic
characteristics and costs assumptions of the United States.
Results: Highly efficient theoretic screening tests were characterized by high sensitivity for advanced adenoma
and carcinoma and high patient adherence. All simulated available screening tests were effective at 100% adher-
ence to screening and at expected real-world adherence rates. All tests were cost effective below the threshold of
100,000 U.S. dollars per life year gained. With perfect adherence, FIT was the most effective and cost-efficient
intervention, whereas Epi proColon was the most effective at expected real-world adherence rates. In our sensi-
tivity analysis, assumptions for patient adherence had the strongest impact on effectiveness of screening.
Conclusions: Our microsimulation study identified characteristics of highly efficient theoretic screening tests
and confirmed the effectiveness and cost-effectiveness of colonoscopy and available urine-, blood-, and stool-
based tests. Better patient adherence results in superior effectiveness for CRC prevention in the whole popula-
tion. (Gastrointest Endosc 2021;94:379-90.)(footnotes appear on last page of article)urnal.org Volume 94, No. 2 : 2021 GASTROINTESTINAL ENDOSCOPY 379
Adherence determines CRC screening effectiveness Deibel et alColorectal cancer (CRC) is the third most common can-
cer in the world1 and causes the fourth highest number of
cancer-related deaths, resulting in high economic impact.2
However, CRC offers optimal opportunities for preventive
efforts because malignant transformation occurs slowly via
adenomatous precursors, and early CRC has much lower
mortality compared with advanced disease.3-6 Therefore,
CRC screening is recommended by current gastroentero-
logic guidelines,7,8 although CRC screening is limited by
low patient adherence.9-13 Increasing patient participation
in CRC screening remains a central task in current gastro-
enterology practice.
The effectiveness of 2 screening principles has been es-
tablished: (1) detection of biomarkers (eg, occult blood by
the guaiac fecal occult blood test) in stool and (2) visual
detection of (pre-)cancerous lesions by endoscopy. The
guaiac fecal occult blood test and rectosigmoidoscopy can
reduce the relative risk for CRC-related mortality by 16%
and 31%, respectively.4,5 The effect of colonoscopy has not
been tested in randomized controlled trials, but many
observational studies suggest a risk reduction of more
than 60%.6 Recently, tests detecting DNA with CRC-
associated mutations in stool or blood have been advanced.
Epi proColon (Epigenomics Inc, Berlin, Germany) is based
on the detection of DNA in the blood with methylated cyto-
sine in the v2 region of the SEPT9 gene, as found predomi-
nantly in colon cancer tissue.14 ColoGuard (Exact Sciences,
Madison, Wisc, USA) is a stool-based multitarget DNA test
that includes quantitative molecular assays for K-ras muta-
tions, aberrant NDRG4 and BMP3 methylation, and b-actin,
plus a hemoglobin immunoassay.15 For both, high
sensitivity for CRC has been shown, whereas for adenoma
it was lower.14,15 Another similarly effective approach is
the urine metabolomic test called PolypDx (PolypDx,
Metabolomic Technologies Inc, Edmonton, AB, Canada),
in which key metabolites are quantified and analyzed by a
multivariate algorithm.16-19 However, for none of these
newer tests, effectiveness regarding reduction of CRC inci-
dence and mortality has been shown in clinical trials.
In the search for a highly efficient screening test, sensi-
tivity and specificity are just one part of the equation. Clin-
ical experience shows that adherence of patients to
diagnostic tests may differ substantially and could depend
on different aspects, such as invasiveness, required prepa-
ration, or associated feeling of shame. The test modality
seems to play an important role. In the case of colon can-
cer screening, no comparative study regarding patient pref-
erences of testing modality has been undertaken. In the
literature, uptake of colonoscopy screening is reported to
be w56% over a 10-year period.11,12 Clinical trials
involving screening of the general public for various
diseases show moderate willingness to undertake stool-
and urine-based tests (w49.3% and 51.4%)10,20-26 and
higher willingness for blood tests (w68%).27,28 In
addition, the interval timing of a screening test can have
a significant impact on its effectiveness, especially in380 GASTROINTESTINAL ENDOSCOPY Volume 94, No. 2 : 2021regard to the previously mentioned parameters.
Hypothetically, repetitive use of a screening test with a
lower sensitivity or adherence but short test interval can
outperform another test with better test characteristics
but longer test intervals (ie, colonoscopy). Last, a
screening test has to be (the most) cost effective to
justify its application. For many questions regarding CRC
screening and prevention, randomized controlled trials
are impracticable because of the large parameter space
and the ethical and logistical challenges. Therefore,
computational approaches have been developed, which
simulate the natural history of CRC and screening
interventions in a large patient population.29,30 Colon
modeling open source tool (CMOST) is an open-source
computational microsimulation tool, with similar predic-
tions compared with randomized CRC prevention trials
and other well-established microsimulation tools.30,31
In this study, we first simulated theoretic CRC screening
with a broad variation of key test characteristics in compar-
ison with colonoscopy screening, to identify the characteris-
tics of highly efficient screening tests. Then we used CMOST
to calculate the incidence reduction, mortality reduction,
life-years gained (LYGs), and cost effectiveness of screening
with the available screening modalities: colonoscopy, fecal
immunochemical test (FIT, Eiken Chemical Co, Ltd, Tokyo,
Japan), ColoGuard, Epi proColon, and PolypDx, including
various assumptions regarding screening adherence.METHODS
We simulated the use of several theoretic screening tests
and varied 5 parameters independently: (1) sensitivity for
early adenoma detection, (2) sensitivity for advanced ade-
noma detection, (3) sensitivity for carcinoma detection,
(4) test specificity, and (5) adherence to testing. The first
and second tests were varied in a range from 0% to 100%
in 10% steps, and the third, fourth, and fifth tests were varied
from 10% to 100% in 10% increments. Furthermore, for
plausibility, sensitivity for cancer detection needed to be at
least as good as the sensitivity for advanced adenoma detec-
tion, and the sensitivity for advanced adenoma detection
needed to be at least as good as the sensitivity for early ade-
noma detection (SensCancer  SensAdvAd  SensEarlAd), re-
sulting in the exclusion of several potential tests. Each test
was applied either yearly or every 2, 3, 4, or 5 years, resulting
in 142,501 theoretic tests. Adherence to follow-up colonos-
copy after a positive test result was assumed to be 82%.32,33
The results of theoretic tests were comparedwith the results
of CRC screening with colonoscopy at 100% adherence at
ages 50, 60, and 70 years. Predictive models for discounted
life-years gained (dLYG) and discounted U.S. dollars
(dUSD) saved were calculated by a stepwise regression
method that automatically adds or removes predictors
(test characteristics in our case) starting from a constant
model. More precisely, at each step of themethod we addedwww.giejournal.org
Deibel et al Adherence determines CRC screening effectivenessor removed a predictor term to the model if the P-value for
an F-test of the change in the resulting sum of squared error
was smaller than <.05 and and larger than >.1, respectively.
We constrained the model to linear terms only (no interac-
tions were considered), and the method stopped when no
term was selected for removal or addition.
The model structure and basic assumptions of CMOST
have been described previously.31 CMOST observes a
given population from birth until death (maximum age,
100 years). The age distribution corresponds to a stable
population without migration, with declining population
size with increasing age. The ethnicity would correspond
to the average distribution in the United States in the
years 2005 to 2009 (66% white, 15% Latino-American,
12% African-American, 4% Asian-American) but has not
been explicitly modeled. The sex distribution is 1:1 for
male:female. For the natural history, the model was cali-
brated to reproduce the age- and sex-specific adenoma
prevalence rates as well as carcinoma incidence and mor-
tality from the Surveillance Epidemiology and End Results
(SEER) Program database for 2005 to 2009. CRC develops
through adenomatous precursors or spontaneous. CMOST
considers 6 distinct adenoma stages, depending on size,
and 4 cancer stages. Adenoma initiation and progression
as well as cancer progression, screening, and surveillance
are all modeled in time increments of 3 months. Adenomas
can be detected during diagnostic examinations such as
endoscopy. Cancer can be diagnosed by screening at an
early stage or by symptoms. After detection, treatment
can cure cancer with a stage-dependent probability.
Compared with the original code,31 the program code
has been optimized for faster computational speed and
now enables calculations with larger patient populations
of 2 million individuals in each run. In contrast to the
original model, CMOST now uses SEER CRC incidence
and mortality data from the years 1988 to 2002,34 before
the onset of widespread CRC screening. The new code is
available at https://github.com/poljan/CMOSTv2.
For the current study, the following screening strategies
were applied: colonoscopy screening according to practice
guidelines,7,8 from age 50 to 75. As recommended by
practice guidelines and/ or the individual manufacturers,
screening with FIT was conducted yearly or biennially
and Epi proColon yearly, whereas ColoGuard and
PolypDx were performed every 3 years. Sensitivity and
specificity for adenoma and carcinoma detection for
ColoGuard,35 Epi proColon,36,37 FIT,10,20-24 and Pol-
ypDx17,19 were taken from the literature (Table 1). A
positive result led to colonoscopy with a given
adherence. Detection probabilities for adenomas of
various sizes were provided (Table 1); detection
probabilities for adenomas would translate nonlinearity to
adenoma detection rates (ADRs) (Supplementary Fig. 1,
available online at www.giejournal.org). ADR is defined as
the percentage of screening colonoscopies with 1
adenoma and is widely used in clinical practice. For awww.giejournal.orgsingle screening colonoscopy at age 60 years, our
baseline adenoma detection probabilities would translate
to an ADR of w15% in women and w27% in men. The
detection and removal of adenoma and/or cancer led to
endoscopic surveillance, with intervals as recommended
by practice guidelines (5 years after nonadvanced
adenoma detection, 3 years after advanced adenoma
detection with lifelong 5-year intervals).38 Noninvasive
screening was resumed at the earliest 10 years after
inconspicuous colonoscopy. Finally, for the purpose of
comparison, a no-screening strategy was also run.
Regarding adherence to screening, 2 scenarios were of
interest: full (100%) and real-world adherence. The pur-
pose of the prior scenario was to capture the full potential
of each screening modality and thereby provide a contrast
point to better understand the influence of adherence on
the simulation outcome. Here, adherence to screening
was 100% for all available screening tests, as well as diag-
nostic and surveillance colonoscopy after a positive result.
For the real-world scenario, adherence was derived from
the literature. Here, colonoscopy screening was assumed
to have an annual adherence of 0.0822, resulting in a 10-
year adherence of 0.56.11,12 Several large studies have
shown the adherence to FIT to average w0.493.10,20-24
The adherence to ColoGuard (stool) was assumed to be
the same. Uptake of PolypDx (urine) and Epi proColon
(blood), was assumed to be similar to the willingness of
the general public to undergo microalbuminuria or pros-
tate specific antigen (PSA) and dyslipidemia screening,
respectively (0.514, 0.68).25-28 Adherence to diagnostic
and surveillance colonoscopy after positive screening was
0.82 in the real-world scenario.32,33
The cost assumptions for the United States were taken
from a recent study39 and transformed to 2018 U.S. dollars
(Supplementary Table 1, available online at www.
giejournal.org).40 In CMOST, costs are computed at 3-
month intervals. Three time periods are distinguished:
the first 12 months after diagnosis, the last 12 months
before CRC-related death, and the follow-up period in be-
tween, with a maximum total of 5 years after cancer diag-
nosis. Overlap of periods is not possible. In a case of
short survival after diagnosis, the last period took prece-
dence. CRC-related costs differ according to CRC stage
(Supplementary Table 1). In a case of death unrelated to
CRC, additional costs apply as described.39 When
indicated, costs and life-years gained were discounted by
3% per year after the start of screening at age 50. Costs
for colonoscopy, FIT, Epi pro Colon, ColoGuard, and Pol-
ypDx screening were derived from the Centers for Medi-
care and Medicaid Services, 2018 Clinical Laboratory Fee
Schedule Public Use File.41 Here, the costs for
colonoscopy include only moderate sedation by the
gastroenterologist, not full anesthesia care. The costs
calculated in the nonendoscopic screening scenarios
include those for colonoscopy resulted by a positive
screening test result. The model does not distinguishVolume 94, No. 2 : 2021 GASTROINTESTINAL ENDOSCOPY 381
TABLE 1. Characteristics and assumptions regarding colorectal cancer (CRC) screening tests
Variable Colonoscopy FIT ColoGuard Epi proColon PolypDx
PolypDx
low specificity
Screening interval, y 10 1 3 1 3 3
Specificity 1 0.95 0.87 0.96 0.913 0.800
Sensitivity
Adenoma 2-5 mm 0.65-0.75 0.05 0.17 0.20 0.43 0.53
Adenoma 6-9 mm 0.81-0.87 0.101 0.17 0.20 0.43 0.53
Adenoma 10 mm 0.95 0.22 0.42 0.22 0.43 0.53
CRC 0.95-1 0.7 0.92 0.69 0.75 0.80
Scenario with full adherence
Yearly adherence 1 1 1 1 1 1
Cumulative lifetime adherence 1 1 1 1 1 1
Adherence to diagnostic colonoscopy - 1 1 1 1 1
Scenario with real-world adherence
Yearly adherence 0.0822 0.493 0.493 0.68 0.5135 0.5135
Cumulative lifetime adherence 0.883 0.581 0.785 0.744 0.931 0.931
Adherence to diagnostic colonoscopy - 0.82 0.82 0.82 0.82 0.82
For PolypDx, in addition to the regular tests, characteristics for a variant with lower specificity are provided.
FIT, Fecal immunochemical test.
Adherence determines CRC screening effectiveness Deibel et albetween true- and false-positive tests. Cost effectiveness
was calculated on a comparison with no screening, with
a cutoff of 100,000 dUSD per dLYGs considered cost effec-
tive and values below zero considered cost saving.
For all analyses, CMOST was used, and calculations were
performed on a high-performance Linux cluster. A popula-
tion of 2 million individuals was simulated in each individ-
ual run. The results are the average of 10 replicate analyses.
For all outcomes, normal distribution of the replicates was
confirmed through the Anderson-Darling test and are
shown as means with the respective standard deviations.
Postprocessing analyses were performed with customized
scripts in Matlab, version R2018b. Data were further pro-
cessed with Excel (version 16, Microsoft, Redmond,
Wash, USA) and Graphpad Prism (version 8, Graphpad,
San Diego, Calif, USA).
For the sensitivity analysis we focused on 3 model
output variables: (1) incidence reduction, (2) life-years
gained, and (3) dUSD per dLYG. We assessed the uncer-
tainty (perturbations) of 8 model parameters: (1) adher-
ence to screening, (2) adherence to test follow-up, (3)
probability of adenoma detection during colonoscopy
(eg, due to suboptimal bowel preparation42), (4) risk for
colonoscopy adverse events, (5) screening cost, (6)
treatment cost, (7) test sensitivity, and (8) test specificity.
Each set of variables was perturbed within a specified
range (Supplementary Table 1) by use of a uniform
random variable. All variables and sensitivity indicesd
defined as fraction of total output variance generated by
the uncertainty in the respective parameter valuedwere
perturbed simultaneously by the Fourier Amplitude
Sensitivity Test (FAST) sampling method.43 The higher382 GASTROINTESTINAL ENDOSCOPY Volume 94, No. 2 : 2021the value of the sensitivity index, the more influential is
the uncertainty (variation) in the parameter compared
with the others. Correlation coefficients between
analyzed model output variables and sampled model
parameters were calculated by the Pearson method.RESULTS
Key characteristics of highly efficient screening
tests
Colonoscopy screening is assumed to be highly efficient
for prevention of life-years lost to CRC. We were looking for
highly efficient screening tests that would be able to match
or outperform the efficiency of colonoscopy screening. We
systematically varied the sensitivity for early and advanced
adenoma, carcinoma, test specificity, adherence, and the
frequency with which this hypothetical test was applied.
All theoretic tests were compared with colonoscopy
screening regarding dLYG and costs (see Methods).
Out of 142,501 theoretic tests, 6299 tests savedmore life-
years than standard colonoscopy screening (Fig. 1A). When
characteristics of efficient screening tests were looked at, all
of them were associated with moderate adherence (at least
w50%). Further, efficient tests had a sensitivity threshold
for advanced adenomas of at least w40% and carcinomas
of at least w70%, with a specificity of at least w40%
(Fig. 1B). Most theoretic efficient tests were applied yearly
or biyearly, and almost no efficient tests were used less
frequently than every 4 years (Fig. 1B). Life-years gained
and costs saved associated with the use of these tests fol-
lowed closely simple linear equations (Fig. 1C).www.giejournal.org
Figure 1. Characteristics of highly efficient colorectal cancer (CRC) screening tests. A, Simulation of 142,501 theoretical CRC screening tests with varying
sensitivities for early and advanced adenoma as well as CRC, varying specificity, adherence to testing, and test intervals. Displayed are discounted life-years
gained as well as discounted costs compared with colonoscopy screening with 100% adherence. Blue dots, inefficient tests compared with colonoscopy.
Red dots, tests that save a higher number of discounted life-years compared with colonoscopy. B, Key characteristics of highly efficient theoretic tests,
surpassing effectiveness of colonoscopy. Highly efficient tests tended to have higher sensitivity for advanced adenoma and CRC, as well as high specificity
and adherence to testing and a test interval of 1 or 2 years. C, Effectiveness (discounted life-years gained, upper panel) and costs (discounted U.S. dollars,
lower panel) of highly efficient tests are plotted according to the test interval. We performed stepwise linear regression to predict effectiveness and costs
of highly efficient tests from the indicated screening parameters (red line).
www.giejournal.org Volume 94, No. 2 : 2021 GASTROINTESTINAL ENDOSCOPY 383

























































































Colonoscopy FIT FIT, 2y Epi proColon ColoGuard PolypDx
100% Adherence
Expected Adherence




Figure 2. Colorectal cancer (CRC) screening with full and real-world adherence. A, CRC incidence reduction. B, CRC mortality reduction. C, Life-years
gained because of CRC screening. D, Cost effectiveness for each screening interventions.
Adherence determines CRC screening effectiveness Deibel et alSimulation of CRC screening strategies with
hypothetical 100% adherence to screening
In the hypothetical scenario with 100% patient adher-
ence, colonoscopy screening reduced CRC incidence by
55% and mortality by 62% compared with no screening
(Fig. 2A and B). Colonoscopy screening resulted in the
gain of 71.6 discounted life-years per 1000 individuals
(Fig. 2C). Colonoscopy-based CRC screening was cost
effective compared with no screening, with 2101 dUSD
for each dLYG (Fig. 2D, Table 2).
All nonendoscopic screening tests reduced CRC inci-
dence and mortality and resulted in a gain in life-years
(Fig. 1). Here, the yearly FIT and Epi proColon tests
were the most effective, surpassing even colonoscopy
screening (Fig. 2C). Performing FIT biennially led to a
significant reduction of this effectiveness. Compared with
no screening, all tests were cost effective with <50,000
dUSD per dLYG; only the FIT and PolypDx were cost
saving (Fig. 2D, Table 2) (Supplementary Fig. 2, available
online at www.giejournal.org).
Simulation of CRC screening with expected,
test-specific adherence rates
Compared with the hypothetical 100% adherence, the
incidence and mortality reduction of all screening tests
were reduced, as were the life-years gained (Fig. 2).
Owing to higher adherence to blood-based tests, Epi pro-
Colon now achieved a discrepantly higher gain of dis-
counted life-years. However, compared with the prior
scenario, the cost effectiveness of all screening tests384 GASTROINTESTINAL ENDOSCOPY Volume 94, No. 2 : 2021increased and now, next to FIT and PolypDx, colonoscopy
was also cost saving (Fig. 2D, Table 2, Supplementary
Fig. 2) when compared with no screening.
Incremental cost-effectiveness ratio
To compare the cost-effectiveness of all screening
methods, incremental cost-effectiveness ratios (ICERs)
were calculated. For hypothetical 100% adherence, yearly
FIT was the dominating strategy, yielding the highest num-
ber of dLYG (74.9 discounted life-years per 1000 individ-
uals compared with no screening) at the second lowest
discounted costs (Table 3). Only biennial FIT was slightly
more cost effective, however, yielding in the lowest
number of discounted life-years. For real-life adherence
rates, yearly FIT was surpassed by PolypDx and Epi proCo-
lon in efficacy (55 and 64.2 vs 54.3 dLYG) but was still the
most cost-efficient screening strategy. PolypDx and Epi
proColon came with an incremental cost of 860,378 and
137,060 dUSD per dLYG, respectively (Table 3).
Systematic variation of adherence rates
To demonstrate the impact of screening adherence on
screening effectiveness, we calculated dose-response curves
for each screening strategy (Fig. 3) (Supplementary Fig. 3,
available online at www.giejournal.org). Higher adherence
rates yielded superior effectiveness of all measures of
screening effectiveness. As expected, higher adherence
resulted in higher ICERs compared with no screening for
all screening tests (Fig. 3D). In other words, the lowest
number of dUSD per dLYG was found at very lowwww.giejournal.org
TABLE 2. CRC screening with a theoretic 100% and real-world adherence to the screening intervention
Variable No screening Colonoscopy FIT FIT, 2 y ColoGuard Epi proColon PolypDx
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For each screening modality, a population of 2 million individuals was simulated 10 times. The numbers shown are the means of these 10 simulations. The values of incidence
and mortality reduction as well as LYG, dLYG, and dUSD per dLYG are compared with no screening. Italic numbers represent the real-world scenario; standard deviation is
provided in parenthesis.
CRC, Colorectal carcinoma; FIT, fecal immunochemical test; LYG, life-years gained; dLYG, discounted life-years gained; USD, U.S. dollars, dUSD, discounted U.S. dollars.
Deibel et al Adherence determines CRC screening effectivenessadherence rates, and a rise in adherence increased the
number of dUSD for each dLYG.
Sensitivity analysis
To determine the sensitivity of various performance pa-
rameters including ADR, incidence reduction, life-years
gained, and cost effectiveness to our choice of parameters,
we performed a sensitivity analysis (Fig. 4) (Supplementary
Fig. 4, Supplementary Table 2, available online at www.
giejournal.org). A considerable variation in incidence
reduction and life-years gained was observed (Fig. 4A,
Supplementary Fig. 3). Cost effectiveness also varied;
however, results were almost consistently below a
threshold of 100,000 dUSD per dLYG (Fig. 4A,www.giejournal.orgSupplementary Fig. 4). Incidence reduction and life-years
gained were most sensitive to variations in screening adher-
ence and follow-up colonoscopies (Fig. 4B and C,
Supplementary Fig. 4). Both outcomes were also sensitive
to adenoma detection, but to a lower degree. Cost
effectiveness was mainly sensitive to variations in screening
and treatment costs (Fig. 4B and C) (Supplementary Fig. 4).DISCUSSION
In this study, we used the open-source microsimulation
tool CMOST to model effectiveness and cost effectiveness
of various screening strategies for CRC. Simulating a largeVolume 94, No. 2 : 2021 GASTROINTESTINAL ENDOSCOPY 385
TABLE 3. Incremental cost effectiveness ratio (ICER) table
100% Adherence
No screening FIT, 2 y PolypDx ColoGuard Colonoscopy Epi proColon FIT
No screening Dominated Dominated $16,169 $2101 $12,209 Dominated
FIT, 2 y $326,866 $749,032 $176,900 $197,180 $5353
PolpypDx $4,267,082 $83,170 $152,150 Dominated





No screening Colonoscopy FIT, 2 y ColoGuard FIT PolypDx Epi proColon
No screening Dominated Dominated $14,965 Dominated Dominated $7530
Colonoscopy Dominated $119,349 Dominated $7978 $40573
FIT, 2 y $19,7403 Dominated $50,014 $65433




Read left to right. The tables shows the relationship of index screening method (left) compared with another screening method shown above. The numbers illustrate the costs
per life-year gained. If a screening method is surpassed at life-years gained at lower costs, it is considered to be dominated by the other. All calculations were done with
discounted life-years and costs. Upper part of table: 100% adherence. Lower part of table: real-word adherence rates.














20 40 60 80 1000































































Adherence per year (in %) Adherence per year (in %)









Colonoscopy FIT FIT, 2y Epi proColon Cologuard PolypDx
40




Figure 3. Systematic variation of screening adherence. A, Colorectal cancer (CRC) incidence reduction. B, CRC mortality reduction. C, Life-years gained
because of CRC screening. D, Cost effectiveness for each screening intervention. Cost effectiveness at low adherence showed pronounced stochastic var-
iations for some tests even with large study populations; therefore, the range from 0% to 5% is not shown. FIT, Fecal immunochemical test.
Adherence determines CRC screening effectiveness Deibel et alrange of theoretic screening tests, we identified tests char-
acterized by good advanced adenoma and carcinoma sensi-
tivity and test adherence that could outperform even386 GASTROINTESTINAL ENDOSCOPY Volume 94, No. 2 : 2021colonoscopy screening with perfect adherence. When
simulated available screening tests, yearly FIT, and yearly
Epi proColon saved the highest number of life-yearswww.giejournal.org
Figure 4. Sensitivity analysis results for colonoscopy (colo), FIT, and PolypDx. Selected model parameters were varied simultaneously. A, Boxplots of
analyzed output variables. Shown are medians (horizontal lines), 25th and 75th percentiles (bottom and top of boxes, respectively). Whiskers show min-
imal and maximal values after removal of outliers (values outside of 1.5  interquartile range). B, Pearson correlation coefficients between each perturbed
parameter and analyzed output variables. *, **, and *** denote P values < .05, < .01, and < .001, respectively. C, First-order sensitivity indices, defined as
the fraction of the total variance in the output variable explained by the variation in each parameter value, calculated by the Fourier amplitude sensitivity
test. Unexplained part refers to the part of variance that cannot be attributed to any single parameter and is related to higher-order interactions between
parameters. LY, Life-years; USD, U.S. dollars; disc., discounted. FIT, fecal immunochemical test.
www.giejournal.org Volume 94, No. 2 : 2021 GASTROINTESTINAL ENDOSCOPY 387
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Adherence determines CRC screening effectiveness Deibel et alwhen 100% adherence to screening was assumed. The ef-
ficiency of all available screening modalities did not differ
greatly, but their cost effectiveness did. Here, the cheap
FIT performed best and was even cost saving.
As demonstrated by our adherence titration, incidence
reduction and the number of life-years gained by each
screening modality critically depends on adherence to
screening protocol. When real-world adherence rates were
applied, our simulation thus shows a superior effectiveness
of some noninvasive screening methods compared with co-
lonoscopy. Our sensitivity analysis also demonstrates that
the effectiveness of screening strategies was strongly depen-
dent on adherence to the screening test and follow-up colo-
noscopies, more so than on the individual test’s sensitivity
for detecting CRC. Therefore, a noninvasive test with high
acceptance could outperform even colonoscopy regarding
CRC and adenoma detection. Given that patient preferences
naturally differ between individuals, an ability to offer a vari-
ety of tests and patient-centered counseling might be
optimal for improving adherence.
We identified several theoretic tests that could outper-
form colonoscopy screening. This seems counterintuitive
because all adenomas and carcinomas were only detected
and/or removed by colonoscopy. However, the higher
testing frequency of noninvasive screening tests allowed in
our simulations for an efficient early detection of advanced
lesions. The effects of an increased testing frequency would
be similar to those of improved testing adherence.
In our calculations, all screening strategies were effective
and cost effective (<100,000 dUSD/dLYG) at preventing
CRC. Cost effectiveness was primarily dependent on
screening and treatment costs. Having the lowest price by
far allows FIT to remain highly cost effective despite yearly
application. The high test specificity for FIT compared favor-
ably with those of most other noninvasive screening tests
except Epi proColon and likely also contributed to its cost
effectiveness. At real-world adherence rates, the effective-
ness of FIT was only slightly surpassed by Epi proColon
and PolypDx at additional costs (ICER) of 137,060 and
860,378 dUSD/dLYG, respectively. In the same scenario, 3
screening tests (colonoscopy, FIT, and PolypDx) were cost
saving. However, with an increasing number of expensive
drug therapies for advanced CRC, the cost effectiveness of
all screening tests can be expected to rise.
Our study has several strengths and limitations. (1) We
use a novel, versatile, and open-source microsimulation
tool, validated against existing tools and literature data,
and freely available to reproduce all simulation results.31 In
contrast to proprietary microsimulation tools, our
calculations can be independently validated and advanced.
(2) Improved CMOST implementation combined with
substantial computational power allowed us to simulate
very large populations and enabled us (3) to explore
>140,000 theoretic tests to identify characteristics of
highly efficient tests and (4) to simulate a high number of
scenarios in our extensive sensitivity analysis, thus388 GASTROINTESTINAL ENDOSCOPY Volume 94, No. 2 : 2021increasing confidence in our results. Limitations include
(1) the in silico nature of our study, necessarily relying on
assumptions from the literature for all variables. Therefore,
recent increases in the incidence of colorectal cancer are
not taken into account, and serrated polyps are not
included. (2) The natural history of CRC is partially
unknown, and the adenoma dwell timedthe average time
an adenoma would reside in the colon until
transformation to CRCdhas not been empirically
determined.29,30 CMOST assumes an average dwell time of
13 years, but shorter assumptions of the dwell time might
result in a lower efficiency of strategies partially relying on
early adenoma detection, such as colonoscopy. (3)
Calibration of CMOST and cost assumptions were specific
to the CRC epidemiology and health economy of the
United States, and our calibrations might not be applicable
to other geographic regions. For instance, a lower CRC
incidence and/or lower CRC treatment costs in developing
countries would fundamentally change the results of our
calculations. (4) For the United States, the costs for
colonoscopy provided by the Medicare and Medicaid 2018
Clinical Laboratory Fee Schedule Public Use File include
only moderate sedation but not anesthesia care.
Performing colonoscopy under full anesthesia would result
in a less favorable cost effectiveness. (5) A scenario with
patient-specific screening preferences and application of
CRC screening according to patient choices has not been
modeled because of the complexity of that scenario.
In summary, we report the efficacy and cost effective-
ness of a variety of CRC screening approaches. Our results
point to the crucial importance of adherence to screening.
Thereby, incidence and mortality reduction by a test with a
lower efficacy but better adherence and/or testing fre-
quency can surpass the effectiveness of colonoscopy in a
population-based screening program.ACKNOWLEDGMENTS
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Deibel et al Adherence determines CRC screening effectivenessAPPENDIX 1.
METHODS
Two thresholds for PolypDx were analyzed in this study:
(1) Specificity of 91% and sensitivity 43% for adenomas1
and 74% for colorectal cancer (CRC).2 (2) Specificity of
80% and sensitivity of 53% for adenomas1 and 80% for
CRC.2RESULTS
Variation in PolypDx Specificity
Specificity for colorectal cancer was similar between the
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Supplementary Figure 1. Relationship between detection probabilities of
screening colonoscopy at age 60 years with detection of adenomas accordin
percentage of colonoscopies with at least 1 early or advanced adenoma dete
parameters were decreased and increased as indicated (censored at 100
calculations with 20 million individuals.
www.giejournal.org Vo0.95 for FIT). We simulated another version of PolypDx
with reduced specificity (0.80 instead of 0.91) but higher
sensitivity for adenomas (0.53 instead of 0.43) and CRC
(0.8 instead of 0.74). With 100% adherence, incidence
and mortality reduction slightly increased (incidence
reduction 51.5% compared with 49.4%; mortality reduction
60.3% compared with 59.2% along with a decrease in cost
effectiveness (586 discounted U.S. dollars [dUSD] per
discounted life-year gained [dLYG] compared with 2969
dUSD per dLYG). This was due to a high rise in colonos-
copy numbers after PolypDx with reduced specificity
(Supplementary Table 3).oma detection probability
0% +20% +40% +60% +80%
adenomas and adenoma detection rates (ADR). We simulated a single
g to the probabilities provided in Table 1. The ADR was defined as the
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%). Error bars indicate mean and standard deviation of 10 repeated










































































































Supplementary Figure 2. Effects of colorectal cancer (CRC) screening with full and real-world adherence (Adh.). As in Figure 1, but A, Total number of
colonoscopies. B, Total number of screening tests. C, Number of colonoscopies per CRC case prevented. D, Number of colonoscopies per life-year gained.
E, Total number of CRC cases. FIT, Fecal immunochemical test; exp., expected.
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Supplementary Figure 3. Systematic variation of screening adherence. As in Figure 2, but A, Number of CRC cases. B, Colorectal cancer (CRC) mortality
cases. C, Colonoscopies per CRC case prevented. D, Colonoscopies per life-year gained. E, Total number of colonoscopies. F, Total number of screening
tests. FIT, Fecal immunochemical test.
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Supplementary Figure 4. Sensitivity analysis results for Epi proColon and ColoGuard. As in Figure 3; selected model parameters were varied
simultaneously. A, Boxplots of analyzed output variables. Shown are medians (horizontal lines), 25th and 75th percentiles (bottom and top of boxes,
respectively). Whiskers show minimal and maximal values after removal of outliers (values outside of 1.5  interquartile range). B, Pearson
correlation coefficients between each perturbed parameter and analyzed output variables. indicated; *, **, and *** denote P values < .05, < .01,
and < .001, respectively. C, First-order sensitivity indices, defined as the fraction of the total variance in the output variable explained by the variation
in each parameter value, calculated by the Fourier amplitude sensitivity test. Unexplained part refers to the part of variance that cannot be attributed
to any single parameter and is related to higher order interactions between parameters. disc., discounted; LY, life-years.
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SUPPLEMENTARY TABLE 1. Costs of screening interventions, colonoscopy adverse events, and CRC treatment
CRC screening
Costs screening tests Costs colonoscopy complications
FIT $19.64 Bleeding $1333
Epi proColon $192 Severe bleeding $7723
PolypDx $200 Serosa burn $9269
ColoGuard $508.87 Perforation $14,349
Colonoscopy $1020
Colonoscopy with polypectomy $1260
CRC treatment Stage I Stage II Stage III Stage IV
Year of diagnosis $42,187 $56,621 $68,725 $89,462
Follow-up year $3508 $3301 $4625 $14,005
Year of death $73,383 $73,091 $77,100 $101,627
Year of death, other causes $22,053 $24,676 $19,872 $57,348
Costs were used as described3,4 and adjusted for inflation to 2018 USD.5
CRC, Colorectal cancer; FIT, fecal immunochemical test.
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SUPPLEMENTARY TABLE 2. Strategy for sensitivity analysis
Category Starting value Minimum Maximum
Adherence to screening
Urine-based test 0.836 0.2 0.95
Stool-based test 0.493 0.2 0.95
Blood-based test 0.7 0.2 0.95
Colonoscopy 0.0822 0.05 0.95
Adherence to follow-up
0.75 0.20 1.00
Adenoma detection by colonoscopy
3-mm adenoma 0.30 0.85
5-mm adenoma 0.75 0.35 0.90
7-mm adenoma 0.81 0.40 0.90
9-mm adenoma 0.87 0.40 0.92
Advanced adenoma 10 mm 0.95 0.50 0.99
Sensitivity of screening tests for adenoma and carcinoma detection
FIT: 3-5 mm adenoma 0.05 0.02 0.125
FIT: 6-9 mm adenoma 0.101 0.04 0.25
FIT: advanced adenoma 10 mm 0.22 0.08 0.40
FIT: CRC 0.7 0.30 0.90
PolypDx: 3-9 mm adenoma 0.43 0.172 0.80
PolypDx: advanced adenoma 10 mm 0.43 0.172 0.80
PolypDx: CRC 0.75 0.30 0.90
Epi pro Colon: 3-9 mm adenoma 0 0 0.25
Epi pro Colon: advanced adenoma 10 mm 0 0 0.25
Epi pro Colon: CRC 0.806 0.345 0.92
ColoGuard: 3-9 mm adenoma 0.17 0.0729 0.4
ColoGuard: advanced adenoma 10 mm 0.42 0.18 0.8
ColoGuard: CRC 0.92 0.394 0.95
Specificity of screening tests for adenoma and carcinoma detection
FIT 0.95 0.70 0.98
PolypDx 0.913 0.68 0.96
Epi proColon 0.969 0.72 0.99
ColoGuard 0.87 0.64 0.94
Colonoscopy risk (25%–300%)
Perforation 0.0007 0.000175 0.0021
Death after perforation 0.052 0.013 0.156
Bleeding 0.0011 0.000275 0.0033
Severe bleeding 0.0004 0.0001 0.0012
Death after bleeding 0.0052 0.0013 0.0156
Serosa burn 0.0003 0.000075 0.0009
Screening costs (50%–180%)
Colonoscopy $1020.00 $510.00 $1836.00
Colonoscopy with polypectomy $1260.00 $630.00 $2268.00
FIT $25.00 $12.50 $45.00
PolypDx $475.00 $237.50 $855.00
ColoGuard $508.87 $254.44 $915.97
(continued on the next page)
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SUPPLEMENTARY TABLE 2. Continued
Category Starting value Minimum Maximum
Epi proColon $192.00 $96.00 $345.60
Costs perforation $14,349.00 $7174.50 $25,828.20
Costs bleeding $1333.00 $666.50 $2399.40
Costs severe bleeding $7723.00 $3861.50 $13,901.40
Costs serosa burn $9269.00 $4634.50 $16,684.20
Treatment costs (50%–180%)
First year, stage I $42187.00 $21,093.50 $75,936.60
First year, stage II $56,621.00 $28,310.50 $101,917.80
First year, stage III $68,725.00 $34,362.50 $123,705.00
First year, stage IV $89,462.00 $44,731.00 $161,031.60
Follow-up stage I $3508.00 $1754.00 $6314.40
Follow-up stage II $3301.00 $650.50 $5941.80
Follow-up stage III $4624.00 $2312.00 $8323.20
Follow-up stage IV $14,005.00 $7,002.50 $25,209.00
Final year, stage I $73,383.00 $36,691.50 $132,089.40
Final year, stage II $73,091.00 $36,545.50 $131,563.80
Final year, stage III $77,100.00 $38,550.00 $13,8780.00
Final year, stage IV $101,627.00 $50,813.50 $182,928.50
Death other causes, stage I $22,053.00 $11,026.50 $39,695.40
Death other causes, stage II $19,872.00 $9,936.00 $35,769.60
Death other causes, stage III $24,676.00 $12,338.00 $44,416.80
Death other causes, stage IV $57,348.00 $28,674.00 $103,226.40
For each parameter group, all indicated parameters were varied in the same direction to the same relative extent, assuming a flat distribution. For the combined variation, all
parameters groups were varied in different directions to different extends. The starting value and the minimum and maximum of variations are indicated.
CRC, Colorectal cancer.
SUPPLEMENTARY TABLE 3. PolypDx versus low-specificity PolypDx
Scenario
PolypDx PolypDx (low spec.)
100% adherence Real-world adherence 100% adherence Real-world adherence
CRC cases (per 1000) 34.1 39.1 32.7 36.8
Screening tests (per 1000) 5420 4444 4592 3995
Colonoscopies (per 1000) 1545 1227 1945 1560
Incidence reduction (%) 49.4 41.9 51.5 45.5
CRC deaths (per 1000) 10.4 12.7 10.2 11.9
Mortality reduction (%) 59.2 50.4 60.3 53.5
Total costs (per capita, USD) 6206 6280 6336 6531
LYG (per 1000) 168.7 139.4 172.4 149.0
dLYG (per 1000) 67.6 55.0 69.3 59.0
dUSD (per dLYG) 2696 4931 586 3408
We provide outcome parameters of 2 versions of PolypDx, with a high or lower specificity (0.91 vs 0.80 for CRC (for complete test characteristics see Table 1), for 100%
adherence and real-world adherence, as indicated. The values of incidence and mortality reduction as well as LYG, dLYG, and dUSD per dLYG are compared with no screening.
CRC, Colorectal cancer; dLYG, discounted life-year gained; dUSD, discounted U.S. dollars; LYG, life-years gained; USD, U.S. dollars.
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